For research use only. Not for therapeutic Use.
Rufinamide-15N,d2 is the deuterium and 15N labeled Rufinamide[1]. Rufinamide is a new antiepileptic agent that differs structurally from other antiepileptic agents and is approved as adjunctive therapy for Lennox-Gastaut syndrome (LGS)[2][3].
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
| Catalog Number | R050752 |
| CAS Number | 1795037-48-7 |
| Synonyms | 1-[dideuterio-(2,6-difluorophenyl)methyl]triazole-4-(15N)carboxamide |
| Molecular Formula | C10H6D2F2N315NO |
| Purity | ≥95% |
| InChI | InChI=1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)/i4D2,13+1 |
| InChIKey | POGQSBRIGCQNEG-RPVANBMVSA-N |
| SMILES | C1=CC(=C(C(=C1)F)CN2C=C(N=N2)C(=O)N)F |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [2]. Suter MR, Kirschmann G, Laedermann CJ, Rufinamide attenuates mechanical allodynia in a model of neuropathic pain in the mouse and stabilizes voltage-gated sodium channel inactivated state. Anesthesiology. 2013 Jan;118(1):160-72. [3]. White HS, Franklin MR, Kupferberg HJ, The anticonvulsant profile of rufinamide (CGP 33101) in rodent seizure models. Epilepsia. 2008 Jul;49(7):1213-20. |
